Biotech Values

[ghmm]

SGP:

FYI the portion of the talk on their PI's starts at about 2:14. They don't go into too much detail. They review development of Boceprevir. Currently treatment experienced trial fully enrolled, naive screened 1200 patients. Will be studying with Pegasys. Rash similar to placebo.

SGH-900518 just said QD dosing, favorable resistance profile, phase 2, referenced slides but I only had the audio.

EDIT:
Link for slide presentation http://media.corporate-ir.net/media_files/irol/89/89839/SP_RandD_WEB_Archive_11_24_08.pdf